Physician profile
Paramjit S Panesar
NPI 1982892659
$8,443.69
in general payments reported to CMS, 2019-2025
50 companies · $2,219 in 2025
The $2,219 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $597 · 2021: $870 · 2022: $774 · 2023: $1,227 · 2024: $1,850 · 2025: $2,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,269 · Education: $26.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,269.09 |
| Education | $26.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,764.55 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,070.29 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $668.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $479.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $438.69 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $412.86 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $399.27 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $334.48 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.94 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $261.00 | 2019-2023 | Verquvo, Dificid, Januvia |
| Bayer Healthcare Pharmaceuticals INC. | $232.99 | 2024-2025 | |
| Arbor Pharmaceuticals, INC. | $219.08 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.92 | 2019-2024 | Xifaxan |
| Amgen INC. | $165.15 | 2023-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $142.40 | 2019-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paramjit Panesar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.